A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View

Shagufta Jawaid; Yogesh Joshi; Nauroz Neelofar; Khuzamah Khursheed; Samya Shams; Mansi Chaudhary; Mitali Arora; Karan Mahajan; Firoz Anwar

doi:10.2174/0113816128347223241021111914

A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View

Curr Pharm Des. 2024 Nov 5. doi: 10.2174/0113816128347223241021111914. Online ahead of print.

Authors

Shagufta Jawaid¹, Yogesh Joshi¹, Nauroz Neelofar², Khuzamah Khursheed³, Samya Shams¹, Mansi Chaudhary¹, Mitali Arora¹, Karan Mahajan¹, Firoz Anwar⁴

Affiliations

¹ Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
² Department of Obstetrics and Gynae, Himaliyan Institute of Medical Sciences, Swami Rama Himaliyan University, Jollygrand, Dehradun, Uttarakhand, India.
³ Shri Guru Ram Rai Institute of Medical and Health Sciences. Patel Nagar. Dehradun, Uttarakhand, India.
⁴ Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.

PMID: 39506444
DOI: 10.2174/0113816128347223241021111914

Abstract

Background: Cardiovascular Diseases (CVDs) are the leading cause of global morbidity and mortality, necessitating innovative approaches for both therapeutics and diagnostics. Nanoscience has emerged as a promising frontier in addressing the complexities of CVDs.

Objective: This study aims to explorethe interaction of CVDs and Nanomedicine (NMs), focusing on applications in therapeutics and diagnostics.

Observations: In the realm of therapeutics, nanosized drug delivery systems exhibit unique advantages, such as enhanced drug bioavailability, targeted delivery, and controlled release. NMs platform, including liposomes, nanoparticles, and carriers, allows the precise drug targeting to the affected cardiovascular tissues with minimum adverse effects and maximum therapeutic efficacy. Moreover, nanomaterial (NM) enables the integration of multifunctional components, such as therapeutic agents and target ligands, into a single system for comprehensive CVD management. Diagnostic fronts of NMs offer innovative solutions for early detection and monitoring of CVDs. Nanoparticles and nanosensors enable highly sensitive and specific detection of Cardiac biomarkers, providing valuable insights into a disease state, its progression, therapeutic outputs, etc. Further, nano-based technology via imaging modalities offers high high-resolution imaging, aiding in the vascularization of cardiovascular structures and abnormalities. Nanotechnology-based imaging modalities offer high-resolution imaging and aid in the visualization of cardiovascular structures and abnormalities.

Conclusion: The cross-talk of CVDs and NMs holds tremendous potential for revolutionizing cardiovascular healthcare by providing targeted and efficient therapeutic interventions, as well as sensitive and early detection for the improvement of patient health if integrated with Artificial Intelligence (AI).

Keywords: Cardiovascular diseases; artificial intelligence.; diagnostics; imaging; nanomedicine; therapeutics.